Publication: Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain.
Loading...
Identifiers
Date
2019
Authors
Couce, María Luz
Sánchez-Pintos, Paula
Aldámiz-Echevarría, Luís
Vitoria, Isidro
Navas, Victor
Martín-Hernández, Elena
García-Volpe, Camila
Pintos, Guillem
Peña-Quintana, Luis
Hernández, Tomás
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Treatment with nitisinone (NTBC) has brought about a drastic improvement in the treatment and prognosis of hereditary tyrosinemia type I (HT1). We conducted a retrospective observational multicentric study in Spanish HT1 patients treated with NTBC to assess clinical and biochemical long-term evolution.We evaluated 52 patients, 7 adults and 45 children, treated with NTBC considering: age at diagnosis, diagnosis by clinical symptoms, or by newborn screening (NBS); phenotype (acute/subacute/chronic), mutational analysis; symptoms at diagnosis and clinical course; biochemical markers; doses of NTBC; treatment adherence; anthropometric evolution; and neurocognitive outcome.The average follow-up period was 6.1 ± 4.9 and 10.6 ± 5.4 years in patients with early and late diagnosis respectively. All patients received NTBC from diagnosis with an average dose of 0.82 mg/kg/d. All NBS-patients (n = 8) were asymptomatic at diagnosis except 1 case with acute liver failure, and all remain free of liver and renal disease in follow-up. Liver and renal affectation was markedly more frequent at diagnosis in patients with late diagnosis (P T.After NTBC treatment a reduction in tyrosine and alpha-fetoprotein levels was observed in all the study groups, significant for alpha-fetoprotein in no NBS-group (P = .03), especially in subacute/chronic forms (P = .018).This series confirms that NTBC treatment had clearly improved the prognosis and quality of life of HT1 patients, but it also shows frequent cognitive dysfunctions and learning difficulties in medium-term follow-up, and, in a novel way, a high percentage of overweight/obesity.
Description
MeSH Terms
Adult
Child
Cognitive Dysfunction
Cyclohexanones
Delayed Diagnosis
Enzyme Inhibitors
Female
Follow-Up Studies
Humans
Infant, Newborn
Kidney Diseases
Male
Needs Assessment
Neonatal Screening
Nitrobenzoates
Obesity
Prognosis
Quality of Life
Retrospective Studies
Spain
Time-to-Treatment
Tyrosinemias
Child
Cognitive Dysfunction
Cyclohexanones
Delayed Diagnosis
Enzyme Inhibitors
Female
Follow-Up Studies
Humans
Infant, Newborn
Kidney Diseases
Male
Needs Assessment
Neonatal Screening
Nitrobenzoates
Obesity
Prognosis
Quality of Life
Retrospective Studies
Spain
Time-to-Treatment
Tyrosinemias